Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Jenny Yaohua Xue, M.D., Ph.D.

Title
Institution
Department
Address

Research
research activities and funding
The research activities and funding listed below are automatically derived from NIH ExPORTER and other sources, which might result in incorrect or missing items. Faculty can login to make corrections and additions.
Most Recent  |  List All
  1. F30CA232549 (XUE, JENNY YAOHUA) Jul 16, 2018 - Jul 15, 2022
    NIH
    Dissecting the evolution of targeted therapy resistance in BRAFV600E-mutant cancer
    Role: Principal Investigator

Bibliographic
selected publications
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Nokin MJ, Darbo E, Richard E, San José S, de Hita S, Prouzet-Mauleon V, Turcq B, Gerardelli L, Crake R, Velasco V, Koopmansch B, Lambert F, Xue JY, Sang B, Horne J, Ziemons E, Villanueva A, Blomme A, Herfs M, Cataldo D, Calvayrac O, Porporato P, Nadal E, Lito P, Jänne PA, Ricciuti B, Awad MM, Ambrogio C, Santamaría D, Bolero Consortium. In vivo vulnerabilities to GPX4 and HDAC inhibitors in drug-persistent versus drug-resistant BRAFV600E lung adenocarcinoma. Cell Rep Med. 2024 Aug 20; 5(8):101663. PMID: 39094577; PMCID: PMC11384943.
    Citations: 1
    Fields: MedMedicine (General)Translation:HumansAnimalsCells
  2. Kim D, Herdeis L, Rudolph D, Zhao Y, Böttcher J, Vides A, Ayala-Santos CI, Pourfarjam Y, Cuevas-Navarro A, Xue JY, Mantoulidis A, Bröker J, Wunberg T, Schaaf O, Popow J, Wolkerstorfer B, Kropatsch KG, Qu R, de Stanchina E, Sang B, Li C, McConnell DB, Kraut N, Lito P. Pan-KRAS inhibitor disables oncogenic signalling and tumour growth. Nature. 2023 Jul; 619(7968):160-166. PMID: 37258666; PMCID: PMC10322706.
    Citations: 116
    Fields: SciScienceTranslation:AnimalsCells
  3. Zhao Y, Murciano-Goroff YR, Xue JY, Ang A, Lucas J, Mai TT, Da Cruz Paula AF, Saiki AY, Mohn D, Achanta P, Sisk AE, Arora KS, Roy RS, Kim D, Li C, Lim LP, Li M, Bahr A, Loomis BR, de Stanchina E, Reis-Filho JS, Weigelt B, Berger M, Riely G, Arbour KC, Lipford JR, Li BT, Lito P. Diverse alterations associated with resistance to KRAS(G12C) inhibition. Nature. 2021 11; 599(7886):679-683. PMID: 34759319; PMCID: PMC8887821.
    Citations: 147
    Fields: SciScienceTranslation:HumansAnimalsCells
  4. Li C, Vides A, Kim D, Xue JY, Zhao Y, Lito P. The G protein signaling regulator RGS3 enhances the GTPase activity of KRAS. Science. 2021 Oct 08; 374(6564):197-201. PMID: 34618566; PMCID: PMC9295010.
    Citations: 30
    Fields: SciScienceTranslation:HumansAnimalsCells
  5. Zhao Y, Xue JY, Lito P. Suppressing Nucleotide Exchange to Inhibit KRAS-Mutant Tumors. Cancer Discov. 2021 01; 11(1):17-19. PMID: 34003780.
    Citations: 9
    Fields: NeoNeoplasmsTranslation:Humans
  6. Kim D, Xue JY, Lito P. Targeting KRAS(G12C): From Inhibitory Mechanism to Modulation of Antitumor Effects in Patients. Cell. 2020 11 12; 183(4):850-859. PMID: 33065029; PMCID: PMC7669705.
    Citations: 89
    Fields: CelCell BiologyTranslation:Humans
  7. Xue JY, Lito P. Quest for Clinically Effective RAF Dimer Inhibitors. J Clin Oncol. 2020 07 01; 38(19):2197-2200. PMID: 32432945.
    Citations: 3
    Fields: NeoNeoplasmsTranslation:Humans
  8. Xue JY, Zhao Y, Aronowitz J, Mai TT, Vides A, Qeriqi B, Kim D, Li C, de Stanchina E, Mazutis L, Risso D, Lito P. Rapid non-uniform adaptation to conformation-specific KRAS(G12C) inhibition. Nature. 2020 01; 577(7790):421-425. PMID: 31915379; PMCID: PMC7308074.
    Citations: 230
    Fields: SciScienceTranslation:HumansCells
  9. Wang VE, Xue JY, Frederick DT, Cao Y, Lin E, Wilson C, Urisman A, Carbone DP, Flaherty KT, Bernards R, Lito P, Settleman J, McCormick F. Adaptive Resistance to Dual BRAF/MEK Inhibition in BRAF-Driven Tumors through Autocrine FGFR Pathway Activation. Clin Cancer Res. 2019 12 01; 25(23):7202-7217. PMID: 31515463; PMCID: PMC6891193.
    Citations: 21
    Fields: NeoNeoplasmsTranslation:HumansAnimalsCells
  10. Wojtaszek JL, Chatterjee N, Najeeb J, Ramos A, Lee M, Bian K, Xue JY, Fenton BA, Park H, Li D, Hemann MT, Hong J, Walker GC, Zhou P. A Small Molecule Targeting Mutagenic Translesion Synthesis Improves Chemotherapy. Cell. 2019 06 27; 178(1):152-159.e11. PMID: 31178121; PMCID: PMC6644000.
    Citations: 89
    Fields: CelCell BiologyTranslation:HumansAnimalsCells
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact contact@catalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resources@hms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappt@hms.harvard.edu.
Xue's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (72)
Explore
_
Co-Authors (4)
Explore
_
Similar People (60)
Explore
_
Same Department 
Explore
© 2025 President and Fellows of Harvard College
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.